Disclosed are compounds of formula (I): wherein the variables R1, R2, R3 and Z are described herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula I:
1
wherein:
R
1
, R
2
, and R
3
are each independently in each occurrence aryl or heteroaryl;
R
4
is —COOH or tetrazolyl;
A, B, m, n, and r are as defined in the specification;
or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and processes for their preparation.
[EN] NOVEL CHEMICAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES CHIMIQUES
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2005082901A1
公开(公告)日:2005-09-09
This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with the imbalance or inappropriate activity of hYAK3 proteins.
[EN] CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE UTILISES COMME DES ANTAGONISTES D'IP
申请人:HOFFMANN LA ROCHE
公开号:WO2001068591A1
公开(公告)日:2001-09-20
This invention relates to compounds which are generally IP receptor antagonists and which are represented by Formula (I) wherein R?1, R2, and R3¿ are each independently in each occurrence aryl or heteroaryl, R4 is -COOH or tetrazolyl, A, B, m, n, and r are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, processes for their preparation and their use as therapeutic agents.